Drugs and the liver: advances in metabolism, toxicity, and therapeutics

被引:20
作者
Buratti, S
Lavine, JE
机构
[1] Univ Calif San Diego, Ctr Med, Div Pediat Gastroenterol & Nutr, San Diego, CA 92103 USA
[2] Childrens Hosp, San Diego, CA USA
[3] Ctr Hlth, San Diego, CA USA
关键词
D O I
10.1097/00008480-200210000-00007
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Biotransformation of drugs is one of the major functions of liver. Hepatic drug metabolism develops early in organogenesis and continues in postnatal life through puberty. Genetic and developmental studies on hepatic drug metabolism show that immaturity, polymorphisms, and altered balance of different hepatic enzymatic activities affect pharmacologic inactivation and alter the risk of toxic effects of drugs on the hepatic parenchyma. Although drug-induced liver disease is less common in children, several reports of hepatotoxicity are published every year. Furthermore, the increasing use of nonregulated remedies (eg, herbal preparations or recreational drugs) increases the risk of unpredictable and potentially severe reactions. Many significant advances in the treatment of hepatic diseases have been achieved recently. However, differences in clinical features, natural history, and response to treatment between children and adults require evaluation of new therapeutic options in focused pediatric clinical trials. (C) 2002 Lippincott Williams Wilkins, Inc.
引用
收藏
页码:601 / 607
页数:7
相关论文
共 45 条
[31]   Metformin reverses fatty liver disease in obese, leptin-deficient mice [J].
Lin, HZ ;
Yang, SQ ;
Chuckaree, C ;
Kuhajda, F ;
Ronnet, G ;
Diehl, AM .
NATURE MEDICINE, 2000, 6 (09) :998-1003
[32]   Cyclosporin A is a promising alternative to corticosteroids in autoimmune hepatitis [J].
Malekzadeh, R ;
Nasseri-Moghaddam, S ;
Kaviani, MJ ;
Taheri, H ;
Kamalian, N ;
Sotoudeh, M .
DIGESTIVE DISEASES AND SCIENCES, 2001, 46 (06) :1321-1327
[33]   Higher occurrence of hepatotoxicity and rash in patients treated with oxacillin, compared with those treated with nafcillin and other commonly used antimicrobials [J].
Maraqa, NF ;
Gomez, MM ;
Rathore, MH ;
Alvarez, AM .
CLINICAL INFECTIOUS DISEASES, 2002, 34 (01) :50-54
[34]   Metformin in non-alcoholic steatohepatitis [J].
Marchesini, G ;
Brizi, M ;
Bianchi, G ;
Tomassetti, S ;
Zoli, M ;
Melchionda, N .
LANCET, 2001, 358 (9285) :893-894
[35]   The ontogeny of human drug-metabolizing enzymes: Phase II conjugation enzymes and regulatory mechanisms [J].
McCarver, DG ;
Hines, RN .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2002, 300 (02) :361-366
[36]   Peginterferon-α-2a (40kD) -: A review of its use in the management of chronic hepatitis C [J].
Perry, CM ;
Jarvis, B .
DRUGS, 2001, 61 (15) :2263-2288
[37]   Increased risk of antituberculosis drug-induced hepatotoxicity in individuals with glutathione S-transferase M1 'null' mutation [J].
Roy, B ;
Chowdhury, A ;
Kundu, S ;
Santra, A ;
Dey, B ;
Chakraborty, M ;
Majumder, PP .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2001, 16 (09) :1033-1037
[38]   Pemoline hepatotoxicity and postmarketing surveillance [J].
Safer, DJ ;
Zito, JM ;
Gardner, JF .
JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2001, 40 (06) :622-629
[39]   Safety of an ofloxacin-based antitubercular regimen for the treatment of tuberculosis in patients with underlying chronic liver disease: A preliminary report [J].
Saigal, S ;
Agarwal, SR ;
Nandeesh, HP ;
Sarin, SK .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2001, 16 (09) :1028-1032
[40]   Sirolimus for rescue and primary immunosuppression in transplanted children receiving tacrolimus. [J].
Sindhi, R ;
Webber, S ;
Venkataramanan, R ;
McGhee, W ;
Phillips, S ;
Smith, A ;
Baird, C ;
Iurlano, K ;
Mazariegos, G ;
Cooperstone, B ;
Holt, DW ;
Zeevi, A ;
Fung, JJ ;
Reyes, J .
TRANSPLANTATION, 2001, 72 (05) :851-855